| Adjuvant or neoadjuvant treatment with immune checkpoint inhibitors: re-assessing the risk–benefit ratio J Delyon, O Michielin The Lancet Oncology 25 (1), 3-5, 2024 | | 2024 |
| Observational study investigating the level of support from a convolutional neural network in face and scalp lesions deemed diagnostically'unclear'by dermatologists J Delyon, B Schmauch, Y Jacob, M Battistella, C Lebbe EUROPEAN JOURNAL OF CANCER 195, 2023 | | 2023 |
| Letter to the Editor re: Observational study investigating the level of support from a convolutional neural network in face and scalp lesions deemed diagnostically ‘unclear’by … J Delyon, B Schmauch, Y Jacob, M Battistella, C Lebbé European Journal of Cancer 195, 2023 | | 2023 |
| TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro J Delyon, A Vallet, M Bernard-Cacciarella, I Kuzniak, C Reger de Moura, ... Cancers 15 (11), 2888, 2023 | 4 | 2023 |
| Endemic Kaposi’s sarcoma PE Zeinaty, C Lebbé, J Delyon Cancers 15 (3), 872, 2023 | 8 | 2023 |
| Eruptive squamous cell carcinomas following an acute skin inflammatory disease: A series of four cases. P Moghadam, F Herms, B Baroudjian, P Tetu, J Delyon, F Jouenne, ... Journal of the European Academy of Dermatology & Venereology 37 (1), 2023 | | 2023 |
| A differential process mining analysis of COVID-19 management for cancer patients MA Cuendet, R Gatta, A Wicky, CL Gerard, M Dalla-Vale, E Tavazzi, ... Frontiers in Oncology 12, 1043675, 2022 | 6 | 2022 |
| Utilisation de la double immunothérapie par anti-CTLA-4 et anti-PD-1 chez les patients octogénaires et nonagénaires atteints de mélanome en France: premières données de l’étude … C Reichert, L Hachon, C Baldini, V Descamps, C Lebbé, C Allayous, ... Annales de Dermatologie et de Vénéréologie-FMC 2 (8), A96-A97, 2022 | 1 | 2022 |
| Impact pronostique du volume métabolique tumoral chez les patients traités par inhibiteurs de checkpoint immunitaires pour un mélanome avancé P Jallerat, J Delyon, A Martineau, B Baroudjian, W Poudroux, P Merlet, ... Annales de Dermatologie et de Vénéréologie-FMC 2 (8), A51, 2022 | | 2022 |
| Traitement néoadjuvant des carcinomes basocellulaires localement avancés par sonidégib: étude observationnelle rétrospective F Herms, B Baroudjian, J Delyon, P Tétu, C Lebbé, N Basset-Seguin Annales de Dermatologie et de Vénéréologie-FMC 2 (8), A78, 2022 | | 2022 |
| Baseline TMTV and Dmax prognostic value in patients with advanced melanoma treated with first-line immune checkpoint inhibitors L Vercellino, P Jallerat, J Delyon, A Martineau, B Baroudjian, W Poudroux, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 49 (SUPPL 1 …, 2022 | | 2022 |
| Managing immune checkpoint inhibition in transplant recipients C Lebbé, L Biard, J Delyon, J Zuber The Lancet Oncology 23 (8), 969-971, 2022 | 4 | 2022 |
| 18FDG PET assessment of therapeutic response in patients with advanced or metastatic melanoma treated with first-line immune checkpoint inhibitors A Rivas, J Delyon, A Martineau, E Blanc, C Allayous, L Da Meda, P Merlet, ... Cancers 14 (13), 3190, 2022 | 5 | 2022 |
| Comprehensive cancer genomic profiling ATLAS: A pharmacogenomics tool in routine practice F Jouenne, B Louveau, A Sadoux, M Boisson, P Vilquin, J Robert, ... FUNDAMENTAL & CLINICAL PHARMACOLOGY 36, 130-130, 2022 | | 2022 |
| Whole transcriptomic improves therapeutic management of melanoma patients B Louveau, A Sadoux, F Jouenne, M Boisson, P Vilquin, B Baroudjian, ... FUNDAMENTAL & CLINICAL PHARMACOLOGY 36, 129-130, 2022 | | 2022 |
| IL-6 blockade in cancer patients treated with immune checkpoint blockade: a win-win strategy J Delyon, C Lebbe Cancer Cell 40 (5), 450-451, 2022 | 12 | 2022 |
| Yield of FDG PET/CT for defining the extent of disease in patients with Kaposi sarcoma L Pesqué, J Delyon, C Lheure, B Baroudjian, M Battistella, P Merlet, ... Cancers 14 (9), 2189, 2022 | 5 | 2022 |
| PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study J Delyon, L Biard, M Renaud, M Resche-Rigon, J Le Goff, S Dalle, ... The Lancet Oncology 23 (4), 491-500, 2022 | 28 | 2022 |
| Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK B Oulès, S Mourah, B Baroudjian, F Jouenne, J Delyon, B Louveau, ... Virchows Archiv 480 (2), 475-480, 2022 | 8 | 2022 |
| A differential process mining analysis of COVID-19 management for cancer patients HC Jha, T Chen, E Parimbelli, O Michielin, MA Cuendet, R Gatta, A Wicky, ... | | 2022 |
